A produção científica do III é grande e diversificada e nos últimos 5 anos mais de 700 artigos científicos foram publicados. Naturalmente, não é possível colocar toda essa informação nas páginas do III, mas as referências estão à disposição dos interessados. Mostramos aqui exemplos que ilustram a qualidade dos trabalhos, as parcerias entre membros do III e, também, as muitas parcerias externas.

Parte significativa da produção nestes últimos anos girou em torno do grande assunto do momento: a COVID-19. Abaixo uma lista ilustrativa (2022-2024).

• ANDRADE SA; BATALHA-CARVALHO JV; CURI R; WEN F H; COVAS DT; CHUDZINSKI-TAVASSI AM; MORO, ANA M. Equine anti-SARS-CoV-2 serum (ECIG) binds to mutated RBDs and N proteins of variants of concern and inhibits the binding of RBDs to ACE-2 receptor. Frontiers in Immunology, v. 13, p. 871874, 2022.
• BOAVENTURA V S; CERQUEIRA-SILVA T; BARRAL-NETTO M. The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era. LANCET INFECTIOUS DISEASES, v. 23, p. 1, 2023.
• CASTELLI ECC, MATEUS V, NASLAVSKY MS, SCLIAR MO, SILVA NSB, PEREIRA RN, CIRIACO VAO, CASTRO CFB, MENDES-JUNIOR CT, SILVEIRA S, DE OLIVEIRA IM, ANTONIO EC, VIEIRA GF, MEYER D, NUNES K, MATOS LRB, SILVA MVR, WANG JYT, ESPOSITO J, CÓRIA VR, MAGAWA JY, SANTOS K S, CUNHA-NETO E, KALIL J, et al. MUC22, HLA-A, and HLA-DOB variants and COVID-19 in resilient super-agers from Brazil. Frontiers in Immunology, v. 13.
• CASTRO JT, AZEVEDO P, FUMAGALLI MJ, HOJO-SOUZA NS, SALAZAR N, ALMEIDA GG, OLIVEIRA LI, FAUSTINO L, ANTONELLI LR, MARÇAL TG, AUGUSTO M, VALIATE B, FIORINI A, RATTIS B, RAMOS SG, PICCIN M, NONATO OC, BENEVIDES L, MAGALHÃES R, CASSARO B, BURLE G, DORO D, KALIL J, DURIGON E, et al. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. Nature Communications, v. 13, p. 4831, 2022.
• CERQUEIRA-SILVA T; ANDREWS JR; BOAVENTURA V; RANZANI OT; OLIVEIRA VA; PAIXÃO, ES; JÚNIOR, JB; MACHADO, TM; HITCHINGS MDT; DORION M; LIND ML; PENNA G; CUMMINGS DAT; DEAN NE; WERNECK GL; PEARCE N; BARRETO ML; KO AI; CRODA J; BARRAL-NETTO M. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. LANCET INFECTIOUS DISEASES, v. 22, p. 1, 2022.
• CERQUEIRA-SILVA T; DE ARAUJO OLIVEIRA V; PAIXÃO ES; JÚNIOR JB; PENNA GO; WERNECK GL; PEARCE N; BARRETO ML; BOAVENTURA VS; BARRAL-NETTO M. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nature Communications, v. 13, p. 4154, 2022.
• CERQUEIRA-SILVA T; KATIKIREDDI SV; DE ARAUJO OLIVEIRA V; FLORES-ORTIZ R; JÚNIOR JB; PAIXÃO ES; ROBERTSON C; PENNA GO; WERNECK GL; BARRETO ML; PEARCE N; SHEIKH A; BARRAL-NETTO M; BOAVENTURA VS. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. NATURE MEDICINE, v. 28, p. 1, 2022.
• DE CASTRO MV; SILVA MV R; NASLAVSKY MS; SCLIAR MO; NUNES K; PASSOS-BUENO MR; CASTELLI EC; MAGAWA JY; ADAMI FL; MORETTI AIS; DE OLIVEIRA VL; BOSCARDIN SB; CUNHA-NETO E; KALIL J; JOUANGUY E; BASTARD P; CASANOVA J-L; QUIÑONES-VEGA M; SOSA-ACOSTA P; GUEDES JS; DE ALMEIDA NP; NOGUEIRA FCS; DOMONT GB; SANTOS KS; ZATZ M. The oldest unvaccinated Covid-19 survivors in South America. Immunity & Ageing, v. 19, p. 57, 2022.
• DORNELES GP; TEIXEIRA PC; PERES A; RODRIGUES JÚNIOR LC; DA FONSECA, SG; MONTEIRO MC; ELLER S; OLIVEIRA TF; WENDLAND EM; ROMÃO PRT. Endotoxin tolerance and low activation of TLR-4/NF-κB axis in monocytes of COVID-19 patients. JOURNAL OF MOLECULAR MEDICINE-JMM, v. x, p. 1, 2023.
• FERNANDES ER; DE SOUZA APOSTOLICO J; JACINTHO LC; CARNEVALE MARIN ML; VIEIRA DA SILVA JÚNIOR RC; RODRIGUES H; SANTOS KS; COELHO V; BOSCARDIN SB; KALIL J; CUNHA-NETO E; ROSA, DS. Time-dependent contraction of the SARS-CoV-2-specific T-cell responses in convalescent individuals. Journal of Allergy and Clinical Immunology: Global, v. 1, p. 112-121, 2022.
• GRACA L; FARIA AC; RIBEIRO RM. Illuminating a blind spot in SARS-CoV-2 immunity. NATURE IMMUNOLOGY, v. 24, p. 889-890, 2023.
• MEDEIROS GX; SASAHARA GL; MAGAWA JY; NUNES JPS; BRUNO, FR; KURAMOTO, AC; ALMEIDA RR; FERREIRA MA; SCAGION GP; CANDIDO ÉD; LEAL FB; OLIVEIRA DBL; DURIGON EL; SILVA RCV; ROSA DS; BOSCARDIN SB; COELHO V; KALIL J; SANTOS KS; CUNHA-NETO E. Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old. Frontiers in Immunology, v. 13, p. 812126, 2022.
• OLIVEIRA JR; RUIZ CMR; MACHADO RRG; MAGAWA JY; DAHER IP; URBANSKI AH; SCHMITZ GJH; ARCURI HA; FERREIRA MA; SASAHARA GL; DE MEDEIROS GX; JÚNIOR RCVS; DURIGON EL; BOSCARDIN SB; ROSA DS; SCHECHTMAN D; NAKAYA HI; CUNHA-NETO E; GADERMAIER G; KALIL J; COELHO V; SANTOS KS. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Frontiers in Immunology, v. 13, p. 1, 2023.
• SERVIAN CDP, SPADAFORA-FERREIRA M, DOS ANJOS DCC, GUILARDE AO, GOMES-JUNIOR AR, BORGES MASB, MASSON LC, SILVA JMM, DE LIMA MHA, MORAES BGN, SOUZA SM, XAVIER LE, DE OLIVEIRA DCA, BATALHA-CARVALHO JV, MORO AM, BOCCA AL, PFRIMER IAH, COSTA NL, FERES VCR, FIACCADORI FS, SOUZA M, GARDINASSI LG, DURIGON EL, ROMÃO PRT, JORGE SAC, COELHO V, BOTOSSO VF, FONSECA SG. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19. Front Immunol. 14:1206979, 2023.
• MCDONNELL J, et al. COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report. J Clin Immunol. 44(4):86, 2024.
• ADAMI FL, DE CASTRO MV, ALMEIDA BDS, DAHER IP, YAMAMOTO MM, SOUZA SANTOS K, ZATZ M, NASLAVSKY MS, ROSA DS, CUNHA-NETO E, DE OLIVEIRA VL, KALIL J, BOSCARDIN SB. Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals. Front Immunol. 15:1396603. 2024.
• CERQUEIRA-SILVA T, BOAVENTURA VS, PEARCE N, BARRAL-NETTO M. Indirect effectiveness of COVID-19 vaccines in the pre-omicron and omicron periods: A nation-wide test-negative case-control study in Brazil. Int J Infect Dis. 148:107241, 2024.